We report that a cell surface marker, Semaphorin 7a (SEMA7A), is significantly associated with poor prognosis, differentially up-regulated in ACC in comparison with normal adrenal tissues and reflects activation of the FAK and MAPK/ERK signaling pathways in a subset of ACC patients. This evidence concerns the gene SEMA7A and adrenal cortex carcinoma.